Drug Delivery Systems for Metabolic Disorders

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch. Dr. S. Narasimha Murthy is the CSO of Topical Products Testing LLC, USA. He was former Professor of Pharmaceutics and Drug Delivery at the University of Mississippi School of Pharmacy, USA for over 15 years. Dr. Murthy is a pioneer in nanotechnology-based delivery systems, microneedles and microstructured delivery technologies of drug delivery and diagnosis, dermal and transdermal delivery of drugs and nose to brain delivery of therapeutics. His research programs are funded by NIH, FDA, and Pharmaceutical companies. He has published over 130 research papers and presented over 250 scientific posters in various national and international scientific meetings. He has authored two books and over fifteen book chapters. He is serving on the Editorial Board of several journals including AAPS Pharm Sci Tech, DDIP and J Pharm. Sci. He is a consultant to pharmaceutical and medical device companies in the USA, Israel, Italy, and India. Dr. Murthy has received several awards such as the New Investigator award and Cumberl and Researcher of the year from the University of Mississippi, Global Indus Technovator award from MIT, Endowed Chair for Research at the Ohio Northern University and he was inducted as the Fellow of the American Association of Pharmaceutical Scientists in 2017 and was bestowed with Distinguished Scientist award by American Association of Indian Pharmaceutical Scientists. Dr. Murthy is also a scientific philanthropist. He is the Founder Director of a non-profit research organization, Institute for Drug Delivery and Biomedical Research in Bangalore, India (www.IDBresearch.com). Dr. Peter Wich leads the Research Lab for Functional Biopolymers at the University of New South Wales in Sydney (Australia). His primary research interests are in the fields of macromolecular chemistry at the interface between nanotechnology and bioorganic chemistry. His lab focuses on the chemical modification of natural biopolymers with the aim to engineer new multi-functional and biocompatible materials for applications in drug delivery, nanomedicine, bio-catalysis, and 3D printing. Dr. Wich is an expert in the field of biopolymer modification and the (self) assembly of these new biohybrid materials into nanoparticles for dynamic drug delivery systems. Dr. Wich has been awarded more than 20 prizes and scholarships for his research, including the Innovation Prize in Medicinal/Pharmaceutical Chemistry for his work on bioinspired nanomaterials (jointly awarded by the Awarded by the German Chemical and the German Pharmaceutical Society) and the Galenus Technology Prize, for his innovative achievements in the field of Pharmaceutical Technology. In 2016, he was selected as “Young Member” of the Academy of Sciences and Literature in Mainz, Germany. In recognition of his achievements, he was selected in 2019 to represent the element Roentgenium in the IUPAC Periodic Table of Younger Chemists. In 2019 Peter was named Emerging Investigator of the Journal “Soft Matter” and in 2020 he was selected as Polymer Chemistry Emerging Investigator. Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over many years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.

1. Introduction to metabolic disorders 2. Cellular and molecular mechanisms involved in metabolic disorders 3. Current practices in drug delivery for metabolic disorders 4. Recent developments towards treatment of amyloidosis. 5. Advanced drug delivery systems targeting to improve therapeutic outcomes in Porphyria 6. Advanced drug delivery systems targeting Kwashiorkor involving disturbance in protein metabo-lism 7. Advanced drug delivery systems targeting metabolic disorders involving a disturbance in protein metabolism:  Erythropoietic Uroporphyria. 8. Combating Atherosclerosis with novel drug delivery approaches: From benchside to commerciali-zation 9. Advanced drug delivery systems in the management of Gaucher Disease 10. Advanced drug delivery systems focusing the metabolic disorders due to deregulation of lipid me-tabolism: Niemann Pick Disease & Letterer-Siwe disease 11. Novel Drug Delivery system to treat Niemann-Pick disease 12. Novel 3D printing drug delivery system for the prevention and treatment of Atherosclerosis 13. Advanced drug delivery systems to treat Huntington disease: Challenges and opportunities 14. Advanced Drug Delivery Systems for obesity 15. Advanced drug delivery systems probing the metabolic disorder due to deregulation in carbohy-drate metabolism 16. Advanced drug delivery systems dealing with metabolic disorder due to disturbance in hormone metabolism- hypoglycaemia and hyperglycemia, 17. EMERGING drug  delivery in the treatment of hyperpituitarism and hypopituitarism 18. Advanced drug deliver system dealing with metabolisn disorders due to disturbance in harmone metabolism  example Hypoparathyroidism and Hyperparathyroidism 19. An update on development of advanced drug delivery systems for treatment of hyperthyroidism 20. Advanced drug delivery systems involving lysosomal storage disorders for Schinder disease and other disorders 21. Advanced drug delivery systems involving lysosomal storage disorders for Fabry disease 22. Drug delivery systems in Krabbe Disease: Present and prospective approaches. 23. Advanced Treatment Strategies to combat  Tay-Sachs Disease (TSD) 24. Sandhoff Disease: Pathology and Advanced Treatment Strategies 25. Nanomaterial-based drug delivery approaches for metabolic disorders. 26. Eye in Metabolic Disorders: Manifestations and Drug Delivery Systems 27. Advanced drug delivery systems involving mitochondrial disorders 28. Application of phytoceuticals in targeting metabolic disorders 29. Phytonanoparticles towards the treatment of diabetes. 30. Role of Neutraceuticals in metabolic disorders 31. Latest Advances of phytomedicine in drug delivery systems for targeting metabolic disorders. 32. Clinical trials, future prospects and challenges of drug delivery in combating metabolic disorders